What changed in Repligen Corp's latest annual report
In the year ended 31 Dec 2025, Repligen Corp's cash and cash equivalents fell 25.3% to USD 566.02m, from USD 757.36m; shareholders' equity rose 6.8% to USD 2.11bn, from USD 1.97bn; total assets rose 4.2% to USD 2.95bn, from USD 2.83bn.
Year ended 31 Dec 2025. Source: 10-K filed 26 Feb 2026, read it on SEC EDGAR.
USD 757.36m to USD 566.02m
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Net income | -25.51m | 48.89m | Not comparable |
| Total assets | 2.83bn | 2.95bn | Up 4.2% |
| Total liabilities | 856.95m | 843.57m | Down 1.6% |
| Long-term debt | 525.57m | 542.21m | Up 3.2% |
| Cash and cash equivalents | 757.36m | 566.02m | Down 25.3% |
| Shareholders' equity | 1.97bn | 2.11bn | Up 6.8% |
Questions people ask
Is Repligen Corp profitable?
Yes. Net income was USD 48.89m in the year ended 31 Dec 2025. The year before: a net loss of USD 25.51m.
How much cash and debt does Repligen Corp have?
At its latest year end (31 Dec 2025), Repligen Corp reported cash and cash equivalents of USD 566.02m and long-term debt of USD 542.21m.
Where do these numbers come from?
From Repligen Corp's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Repligen Corp?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Biological Products, (No Diagnostic Substances) companies
- Amgen Inc.Net income up 88.5%
- Gilead Sciences, Inc.Net income up 1672.9%
- Moderna, Inc.Revenue down 39.9%
- Revolution Medicines, Inc.Total liabilities up 146.7%
- Biogen Inc.Net income down 20.8%
- Exelixis IncCash and cash equivalents up 122%
- Neurocrine Biosciences IncCash and cash equivalents up 206%
- Halozyme Therapeutics, Inc.Shareholders' equity down 86.6%